Bluebird’s new gene therapy among three new EMA OKs ahead of FDA

Ahead of a usually speedy FDA, the European Medicines Agency on Friday recommended marketing authorizations for bluebird bio’s new gene therapy for children with a rare, inherited neurological disease, GlaxoSmithKline and Vir’s monoclonal antibody treatment for Covid-19, and a new treatment for a rare liver disease.